Market Place
Sourcing Support
Ovid Therapeutics Presents Pre-Clinical Results On OV329
26 Sep 2024 //
GLOBENEWSWIRE
Meg Alexander Becomes President And COO At Ovid Therapeutics
11 Sep 2024 //
GLOBENEWSWIRE
Ovid Therapeutics to Present at Upcoming Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Ovid Halts Preclinical Work, IV Seizure Program After Soticlestat Phase 3
14 Aug 2024 //
FIERCE BIOTECH
Ovid Therapeutics Reports Q2 2024 Results And Business Updates
13 Aug 2024 //
GLOBENEWSWIRE
Ovid Therapeutics Appoints Dr Amanda Banks As Chief Development Officer
08 Aug 2024 //
GLOBENEWSWIRE
Ovid Therapeutics to Present at Upcoming August Investor Conferences
30 Jul 2024 //
GLOBENEWSWIRE
Ovid Therapeutics Expands Scientific Advisory Board With New Appointments
23 Jul 2024 //
GLOBENEWSWIRE
ENeuro Publishes Findings On OV329`s Anti-Convulsant Properties
10 Jul 2024 //
GLOBENEWSWIRE
Ovid And Graviton Report OV888/GV101 Phase 1 Data For CCM
01 Jul 2024 //
GLOBENEWSWIRE
Takeda`s seizure drug fails to meet main goal in late-stage studies
18 Jun 2024 //
REUTERS
Ovid Reports On Takeda’s Phase 3 Topline Results For Soticlestat
17 Jun 2024 //
GLOBENEWSWIRE
Ovid Therapeutics Reports Business Updates, Q1 2024 Results
14 May 2024 //
GLOBENEWSWIRE
Ovid Therapeutics To Present At H.C. Wainwright BioConnect Conference
13 May 2024 //
GLOBENEWSWIRE
Ovid to Present at the 23rd Annual Needham Virtual Healthcare Conference
04 Apr 2024 //
GLOBENEWSWIRE
Marinus Comments on Patent Challenge by Ovid & Provides Update
27 Mar 2024 //
BUSINESSWIRE
Ovid asks USPTO to review Marinus` patent around serious seizure condition
27 Mar 2024 //
ENDPTS
Ovid Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
08 Mar 2024 //
GLOBENEWSWIRE
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Conference
06 Feb 2024 //
GLOBENEWSWIRE
Ovid to Present Five Abstracts at the 77th American Epilepsy Meeting (2023)
01 Dec 2023 //
GLOBENEWSWIRE
Ovid Therapeutics Reports Third Quarter 2023 Financial Results
03 Nov 2023 //
GLOBENEWSWIRE
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement
18 Oct 2023 //
GLOBENEWSWIRE
Ovid sells some royalty rights to Takeda-partnered seizure drug
18 Oct 2023 //
FIERCE BIOTECH
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
10 Oct 2023 //
GLOBENEWSWIRE
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
26 Sep 2023 //
GLOBENEWSWIRE
Ovid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
20 Sep 2023 //
GLOBENEWSWIRE
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
30 Aug 2023 //
GLOBENEWSWIRE
Ovid Therapeutics Reports Q2 2023 Financial Results and Corporate Updates
04 Aug 2023 //
GLOBENEWSWIRE
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
01 Aug 2023 //
GLOBENEWSWIRE
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints CSO
28 Jun 2023 //
GLOBENEWSWIRE
Ovid Therapeutics Added to Russell 3000® Index
26 Jun 2023 //
GLOBENEWSWIRE
Ovid Therapeutics Reports 1Q 2023 Financial Results and Corporate Updates
05 May 2023 //
GLOBENEWSWIRE
Ovid snaps up Rock2 inhibitor from Sam Waksal-led Graviton
01 May 2023 //
FIERCE BIOTECH
Ovid partners with Waksal startup to develop drugs for rare brain disorders
01 May 2023 //
BIOPHARMADIVE
Ovid Announces Collaboration with Graviton Bioscience, ROCK2 Inhibitors
01 May 2023 //
GLOBENEWSWIRE
Long-term Safety &Efficacy Findings from Soticlestat Open Label Extension Study
27 Apr 2023 //
GLOBENEWSWIRE
Ovid to Present at the 22nd Annual Needham Virtual Healthcare Conference
10 Apr 2023 //
GLOBENEWSWIRE
Ovid Reports Business Update, Fourth Quarter & Full Year 2022 Financial Results
13 Mar 2023 //
GLOBENEWSWIRE
Ovid Therapeutics to Present at 2nd Annual Needham Virtual Neuroscience Forum
09 Mar 2023 //
GLOBENEWSWIRE
Studies Published Validate the Potential of Direct KCC2 Activation
08 Mar 2023 //
GLOBENEWSWIRE
Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
28 Feb 2023 //
GLOBENEWSWIRE
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
08 Feb 2023 //
GLOBENEWSWIRE
Ovid brings two Big Pharma vets on board as new CMO, head of epilepsy research
08 Feb 2023 //
ENDPTS
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
05 Jan 2023 //
GLOBENEWSWIRE
Ovid Therapeutics to Present Data on Its Epilepsy Programs at AESAM(2022)
02 Dec 2022 //
GLOBENEWSWIRE
Ovid Therapeutics Reports3Q 2022 Financial Results and Corporate Highlights
08 Nov 2022 //
GLOBENEWSWIRE
Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Conference
27 Sep 2022 //
GLOBENEWSWIRE
gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Acute Withdrawal
07 Sep 2022 //
GLOBENEWSWIRE
Ovid turns to gene therapy startup to restock drug pipeline
25 Aug 2022 //
BIOPHARMADIVE
Ovid Therapeutics Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Ovid Therapeutics Presents Preclinical Data on OV329 at the EFP Conference
06 Jun 2022 //
GLOBENEWSWIRE
Ovid Tx to Present at 21st Annual Needham Virtual Healthcare Conference
08 Apr 2022 //
GLOBENEWSWIRE
Ovid cuts 20% of staff, refocuses on epilepsy
16 Mar 2022 //
FIERCEBIOTECH
Ovid Tx Reports Business Update, Q4 and FY 2021 Financial Results
15 Mar 2022 //
GLOBENEWSWIRE
Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
04 Mar 2022 //
GLOBENEWSWIRE
Ovid pens deal to offload twice-failed former lead program
09 Feb 2022 //
BIOSPACE
Ovid lands AstraZeneca in a comeback licensing deal
04 Jan 2022 //
FIERCEBIOTECH
CorMedix CEO, Khoso Baluch to retire
05 Oct 2021 //
ENDPTS
Biotech incubator Sporos` new CEO arrives from Ovid
29 Sep 2021 //
FIERCEBIOTECH
